Cytoprotection of amifostine (A) in ovarian cancer patients receiving paclitaxel/carboplatin (PC) first line chemotherapy in a multicenter phase III trial

Autor:	Paul Sevelda, U. Sevelda, U. Denison, A. Kaider
Rok vydání:	2004
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry fungi food and beverages Amifostine Who grade medicine.disease Cytoprotection Internal medicine medicine Paclitaxel carboplatin First line chemotherapy Ovarian cancer business medicine.drug
Zdroj:	Journal of Clinical Oncology. 22:5021-5021
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2004.22.90140.5021
Popis:	5021 Background: The primary objectives of the study were to evaluate, if A can prevent or reduce the WHO grade of haematological and non haematological toxicities induced by PC and to determine if...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ed88bd372124be39a875411bdc27b91c https://doi.org/10.1200/jco.2004.22.90140.5021 Zobrazit plný text záznamu